Literature DB >> 19853649

Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer's disease and mild cognitive impairment.

Lars Olson1, Christian Humpel.   

Abstract

Alzheimer's disease (AD) is a severe chronic neurodegenerative disorder of the brain. A probable diagnosis of AD can be obtained by cerebrospinal fluid levels of 3 biomarkers: beta-amyloid (1-42), total tau and phospho-tau181. Researchers are interested in finding additional biomarkers in CSF to improve the specificity and sensitivity of diagnosis, including also other forms of dementia, such as mild cognitive impairment (MCI). In addition, less invasive diagnostic methods using blood or blood-derived cells are being investigated. This mini-review (in concert with the other reviews of this special issue) summarizes the usefulness of growth factors and cytokines/chemokines as putative surrogate biomarkers for diagnosing AD and MCI in CSF and blood. Briefly, the expression levels of growth factors and cytokines/chemokines are very heterogenous, indicating the pathological diversity of these diseases. At present, no single growth factor or cytokine alone stands out as a useful biomarker for diagnosing AD or MCI. However, the combined "patients profile signature" of several selected growth factors and/or cytokines/chemokines may allow to diagnose AD and MCI with higher selectively and specificity. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19853649     DOI: 10.1016/j.exger.2009.10.011

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  17 in total

Review 1.  Brain metabolic dysfunction at the core of Alzheimer's disease.

Authors:  Suzanne M de la Monte; Ming Tong
Journal:  Biochem Pharmacol       Date:  2013-12-28       Impact factor: 5.858

2.  Amyloid-β metabolism in Niemann-Pick C disease models and patients.

Authors:  Niklas Mattsson; Maria Olsson; Mikael K Gustavsson; Marko Kosicek; Martina Malnar; Jan-Eric Månsson; Maria Blomqvist; Johan Gobom; Ulf Andreasson; Gunnar Brinkmalm; Charles Vite; Silva Hecimovic; Caroline Hastings; Kaj Blennow; Henrik Zetterberg; Erik Portelius
Journal:  Metab Brain Dis       Date:  2012-09-01       Impact factor: 3.584

3.  Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility.

Authors:  Niklas Mattsson; Shahrzad Tabatabaei; Per Johansson; Oskar Hansson; Ulf Andreasson; Jan-Eric Månsson; Jan-Ove Johansson; Bob Olsson; Anders Wallin; Johan Svensson; Kaj Blennow; Henrik Zetterberg
Journal:  Neuromolecular Med       Date:  2011-05-13       Impact factor: 3.843

4.  High Blood caffeine levels in MCI linked to lack of progression to dementia.

Authors:  Chuanhai Cao; David A Loewenstein; Xiaoyang Lin; Chi Zhang; Li Wang; Ranjan Duara; Yougui Wu; Alessandra Giannini; Ge Bai; Jianfeng Cai; Maria Greig; Elizabeth Schofield; Raj Ashok; Brent Small; Huntington Potter; Gary W Arendash
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

5.  Biomarkers of primary open-angle glaucoma.

Authors:  Paul A Knepper; John R Samples; Beatrice Yjt Yue
Journal:  Expert Rev Ophthalmol       Date:  2010-12

Review 6.  The Role of Hypoxia-Inducible Factor 1 in Mild Cognitive Impairment.

Authors:  Osigbemhe Iyalomhe; Sabina Swierczek; Ngozi Enwerem; Yuanxiu Chen; Monica O Adedeji; Joanne Allard; Oyonumo Ntekim; Sheree Johnson; Kakra Hughes; Philip Kurian; Thomas O Obisesan
Journal:  Cell Mol Neurobiol       Date:  2016-11-17       Impact factor: 5.046

7.  Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.

Authors:  Pamela Sparks Stein; Michelle J Steffen; Charles Smith; Gregory Jicha; Jeffrey L Ebersole; Erin Abner; Dolph Dawson
Journal:  Alzheimers Dement       Date:  2012-05       Impact factor: 21.566

Review 8.  Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease.

Authors:  Anne M Fagan; Richard J Perrin
Journal:  Biomark Med       Date:  2012-08       Impact factor: 2.851

Review 9.  Novel Neuroprotective Potential of Crocin in Neurodegenerative Disorders: An Illustrated Mechanistic Review.

Authors:  Sareh Kermanshahi; Ghazal Ghanavati; Mobina Abbasi-Mesrabadi; Mina Gholami; Luis Ulloa; Majid Motaghinejad; Sepideh Safari
Journal:  Neurochem Res       Date:  2020-09-17       Impact factor: 3.996

10.  Association of the interleukin 1 beta gene and brain spontaneous activity in amnestic mild cognitive impairment.

Authors:  Liying Zhuang; Xiaoyan Liu; Xiaohui Xu; Chunxian Yue; Hao Shu; Feng Bai; Hui Yu; Yongmei Shi; Zhijun Zhang
Journal:  J Neuroinflammation       Date:  2012-12-01       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.